Replimune Group, Inc. (REPL) Stock
REPL Key Statistics
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
CEO: Sushil Patel. Company website
REPL — Frequently Asked Questions
What is the REPL stock price today?
Replimune Group, Inc. (REPL) trades at $11.20, up 107.02% on the day, as of Sep 20, 2026 14:59 UTC.
What is Replimune Group, Inc.'s market cap?
Replimune Group, Inc. has a market capitalisation of $924.81M, calculated from the live REPL share price and shares outstanding.
What is the P/E ratio of REPL?
REPL has no meaningful price-to-earnings ratio: Replimune Group, Inc. lost $3.58 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Replimune Group, Inc. make?
Replimune Group, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for REPL?
REPL has traded between $1.50 and $12.50 over the past 52 weeks, and the last price is 10.4% below that high.
Is Replimune Group, Inc. profitable?
Yes. Replimune Group, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for REPL?
Wall Street analysts rate REPL Buy, with an average price target of $13.75, 22.8% above the current price.
What sector is Replimune Group, Inc. in?
Replimune Group, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Replimune Group, Inc.?
Sushil Patel is the chief executive of Replimune Group, Inc., which employs 479 people.
Where can I track REPL in real time?
QFI Terminal shows REPL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See REPL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open REPL in Terminal See plans